Chronic mitral valvular insufficiency (CMVI) is probably the most common cause of congestive heart failure (CHF) in dogs. Although, recent advances in veterinary diagnostic imaging technology have enabled us to detect CHF earlier and more accurately, the accuracy and reliability of this technology heavily hinders on the experience and skill of the operator. Assays for cardiac biomarkers are a reliable method for the detection and evaluation of cardiac diseases in humans and dogs. Although, several cardiac biomarkers have been used and being widely used in small animal practice, several problems are encountered and hinders the clinical application of cardiac biomarker assays in small animal practice. Therefore, recent studies focus on developing new type of cardiac biomarkers, which can overcome limitations of pre-existing markers such as NT-pro BNP, cardiac troponins. This review focused on new cardiac biomarkers and patents about calcium related genes involving in myocardial contraction in dogs.
Keywords: Cardiac biomarkers, NCX-1, Hax-1, SERCA2a, PLN, mitral valve disease, CMVI, dogs, Calcium, congestive heart failure, NT-pro BNP, cardiac troponins, CMVI, dogs, eccentric hypertrophy, Atrial natriuretic peptide, NT-pro ANP, glutathione level, RT-PCR, valvular disease, Myoglobin, Cardiac Troponin, Brain Natriuretic Peptide, myocardial dysfunction, CK-MB, necrosis, ischemia, TNF, fibrinogen, plasminogen, platelet function, hypertrophic cardiomyopathy, dihydropyridine receptors, sarcoplasmic reticulum, ryanodine receptors, NCX-1 gene, reverse transcrip-tion polymerase chain reaction